Short answer
CATALYST PHARMACEUTICALS, INC. (CPRX) filed its Q1 2026 10-Q quarterly report on May 11, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $149M (up 5.6% year over year) with net income of $64M.
Q1 2026 key financials · XBRL
- Revenue
- $149M
- +5.6% YoY
- Net income
- $64M
- +12.3% YoY
- Operating margin
- 49.0%
- EPS (diluted)
- $0.50
- +11.1% YoY
Source: XBRL data from the CATALYST PHARMACEUTICALS, INC. (CPRX) Q1 2026 10-Q on SEC EDGAR. USD.
CATALYST PHARMACEUTICALS, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New tariff risk triggered by April 16, 2025 Commerce Department Section 232 pharmaceutical-import probe
- Most materially updated risk: proposed Angelini Pharma merger, with expected third-quarter 2026 closing and $155.5 million potential termination fee
- Regulatory pricing risk from proposed Most Favored Nation drug pricing, with Catalyst not invited to Administration negotiations
- Merger-related litigation risk from potential stockholder class actions delaying or preventing closing
- Supply-chain risk from foreign-sourced AGAMREE ingredients and FYCOMPA supplies through at least 2029
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CATALYST PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.